Study on the Decision Support System of Difficult Airway Evaluation
Launched by PEKING UNIVERSITY THIRD HOSPITAL · Dec 22, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on improving the way doctors predict and manage difficult airways during surgery, specifically for patients undergoing surgery for cervical spondylosis, which is a condition affecting the neck. The researchers are looking at different physical and imaging signs before surgery to create a reliable system that can alert doctors if a patient may have a difficult airway. This will help ensure that patients receive the best care and have safer surgeries.
To be eligible for this study, patients should be between 18 and 75 years old, generally healthy (classified as ASA I-III), and scheduled for elective surgery that requires general anesthesia and tracheal intubation. Unfortunately, those with specific conditions like cervical spine instability, airway diseases, or incomplete medical imaging cannot participate. If you join the study, you can expect to undergo evaluations that help assess your individual risk for a difficult airway, with the goal of improving surgical outcomes. Your participation will contribute to developing better tools for future patients facing similar surgeries.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients of ASA I-III
- • scheduled for elective surgery for cervical spondylosis under general anesthesia with tracheal intubation
- Exclusion Criteria:
- • patients with cervical spine instability
- • oropharyngeal mass
- • airway disease
- • preoperative imaging data were incomplete
- • refuse to sign informed consent
About Peking University Third Hospital
Peking University Third Hospital is a leading medical institution in China, renowned for its commitment to advanced healthcare, innovative research, and comprehensive clinical services. As a prominent sponsor of clinical trials, the hospital emphasizes the integration of cutting-edge scientific research with patient-centered care to enhance therapeutic outcomes. With a multidisciplinary approach, the institution fosters collaboration among top-tier medical professionals and researchers, striving to contribute to the global medical community through rigorous clinical studies that address pressing health challenges. Its dedication to ethical standards and regulatory compliance ensures the safety and efficacy of new treatments, ultimately aiming to improve patient care and outcomes on both a national and international scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Yongzheng Han, M.D.
Study Chair
Peking University Third Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported